Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169
Authors:
- Samir ZaidiSZSamir Zaidi
- Phillip H. KuoPKPhillip H. Kuo
- Tiago Paiva PrudenteTPTiago Paiva Prudente
- Kristine P. LacunaKLKristine P. Lacuna
- Hani M. BabikerHBHani M. Babiker
- Renan AparicioRARenan Aparicio
- Joseph D. SchonhoftJSJoseph D. Schonhoft
- Luisa FernandezLFLuisa Fernandez
- Richard MessmannRMRichard Messmann
- Michael GroaningMGMichael Groaning
- Anthony W. TolcherATAnthony W. Tolcher
- Michael S. GordonMGMichael S. Gordon
- 19 March 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF11
Abstract
Purpose: Prostate-specific membrane antigen (PSMA)–directed therapies provide meaningful clinical benefit in metastatic castration-resistant prostate cancer (mCRPC), yet responses remain limited, underscoring the need for additional biomarkers of PSMA expression heterogeneity. In this study, we explored the relationship between PSMA imaging and PSMA expression on circulating tumor cells (CTC) in our early-phase trial using a PSMA-targeted small molecule. Experimental Design: This phase I study investigated EC1169, a small molecule conjugated to a tubulysin analog warhead, and 99mTc–EC0652, a PSMA imaging agent. Part A (dose escalation) identified the recommended phase II dose. Part B (dose expansion) assessed radiographic progression-free survival (rPFS) as its primary endpoint. We enrolled and treated 103 patients with mCRPC. Most part B patients underwent 99mTc–EC0652 PSMA imaging. A CTC assay assessed PSMA-positive CTCs and their association with response and PSMA imaging. Results: 99mTc–EC0652 single-photon emission computed tomography (SPECT) imaging demonstrated increased sensitivity for detecting bone lesions compared with standard scans (computed tomography/bone scans). Using an optimized CTC assay, we observed that patients with a decrease in PSMA+ CTCs at baseline versus C3D1 displayed a longer rPFS (8 vs. 2.9 months; P = 0.04). Importantly, patients with predominantly PSMA-positive disease on 99mTc–EC0652 imaging also harbored PSMA-negative CTCs, with a subset displaying neuroendocrine prostate cancer–like morphology. Conclusions: Although EC1169 showed limited activity, CTC and imaging analyses showed significant heterogeneity in PSMA expression on CTCs in patients with predominantly PSMA-positive lesions on SPECT. Our study highlights the importance of assessing both PSMA-based CTC and imaging assays in future validation trials.Keywords
All Related Versions
Funding Information
- Endocyte (Industry)
- National Cancer Institute (P30 CA008747)
- National Cancer Institute (P30 CA008747)
This publication has 34 references indexed in Scilit:
- Correspondence Re: Ghosh A and Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528–539, 2004Journal of Cellular Biochemistry, 2004
- Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.2003
- Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigenUrology, 2001
- Prostate-specific membrane antigen is produced in tumor-associated neovasculature.1999
- Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.1999
- Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastasesUrology, 1998
- Constitutive and antibody-induced internalization of prostate-specific membrane antigen.1998
- Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinomaCancer, 1998
- Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.1997
- Expression of the prostate-specific membrane antigen.1994